Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. - Wikidata - awgldk - TriplyDB

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

http://www.wikidata.org/entity/Q46312545

about

Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages Role of immunotherapy for renal cell cancer in 2011 Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer Therapeutic cancer vaccines: past, present, and future PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes Control of the immune response by pro-angiogenic factors The role of regulatory T cells in cancer immunology Recent advances in therapeutic cancer vaccines Targeting the tumor vasculature to enhance T cell activity Sunitinib in the treatment of metastatic renal cell carcinoma Medical treatment of renal cancer: new horizons Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.Interface of signal transduction inhibition and immunotherapy in melanoma.Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia(®)) in Dogs with Spontaneous Malignancies.Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.AACR centennial series: the biology of cancer metastasis: historical perspective The immunocytokine NHS-IL12 as a potential cancer therapeutic Novel immunotherapy in metastatic renal cell carcinoma.Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Oncogene withdrawal engages the immune system to induce sustained cancer regression.Adjuvant therapy for renal cell carcinoma: past, present, and future Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.Targeting immune suppressing myeloid-derived suppressor cells in oncology.Development and application of 'phosphoflow' as a tool for immunomonitoring Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.Deciphering the anticancer mechanisms of sunitinib.

P2860

Q26783748-D9E33AD5-B3BD-4537-99DF-518755AACC7C Q26853453-DD92A8E2-14A3-4996-8D75-200D3586188B Q26861293-B108A132-E897-4CB8-BA36-C1DEC577042A Q26863283-34262B13-CA67-43F4-8ADD-3F5CD68DD53D Q26865789-A49D5F74-3F92-4AB8-9F43-BC9373FB7516 Q26991589-A1685CFF-283C-4C1F-A14C-5ABFFE5EC045 Q26991991-7B5F0241-D135-4CE6-B88D-748176508879 Q27004733-BC0F6CEA-7EBA-4016-9027-15DAE554B7CB Q27006663-67BC8A6A-F5E8-4D54-B4BF-7E20E4D7C0F2 Q27025266-7152002A-58DE-4C7C-A2D5-FA8487A120F9 Q27026329-DC2871D7-A3AD-4AA1-909C-A6DA80CA7130 Q28072057-8225992F-584D-4899-AED5-93649E826003 Q28073174-8F0C6494-AA06-4B0C-9D20-880EB34B5748 Q28080262-0E0EBED9-0418-45E7-A5EB-662F59B7242A Q28082461-083218AB-5AE7-4442-B6D9-A2DFBBCC7CC5 Q28301672-6FEE7415-A6D8-48E0-A59C-B7510F8E8689 Q28393614-32DE6F70-C379-44AC-9009-958CDE21F64D Q30317831-496D4552-9C1A-4C65-83F0-BBDBCE513786 Q30429380-932087AE-4F13-49D8-B8D7-31E4C0E3DAA3 Q30472042-A76E984C-A2B9-45E1-8CA8-622F4E480CE9 Q33393378-A4D89AB0-7AC5-45F9-A4EC-29058675D04E Q33428144-E023CD16-FB24-4EFB-8766-9A7125A3F5C8 Q33606102-DD6008FE-D322-47FA-88E1-8AE97A54C2AC Q33683443-CF1FFFDD-0AE5-4872-BFB9-761FB254CFA3 Q33688398-662F4239-9D27-43D5-A7A9-F980EA99A41C Q33863074-5E5058E2-77B4-4101-A0DA-7CDA6EFF0A2C Q33903025-71AA2AA0-2153-49E1-A4E1-0D8E6CE024E0 Q33987633-8311D486-7D15-4DDF-AD16-A35919C3315D Q34005127-D53B18F6-B410-4E4C-9FAC-19F5005E6E1C Q34059205-181B7A64-D252-4450-9586-D31DD8BA52B2 Q34082067-39535A09-4071-4AF7-BB25-FA856613EC4C Q34105965-9D291818-5A72-487B-BC45-9489A6A85EAC Q34205907-326173A6-CC64-4D57-854A-1D52A2BF0631 Q34315871-7067AC52-7FFA-4DFC-9DB5-8613CC5FF67F Q34361976-92751AD8-9C71-49AB-84E8-FE60AC43F3D9 Q34458617-C8742B23-1D1B-4DFF-B158-FAD18220CAAF Q34473451-B282047D-9348-4966-93C7-76E43554F863 Q34504649-7678670E-290C-4D5F-82EE-9C8619E019B7 Q34648541-A8B64491-D4C2-4FA5-87CC-773C22D68CC1 Q34978840-A4FAF659-7F84-434F-A9F5-8E6F6AF707A9

P2860

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

http://www.wikidata.org/entity/Q46312545

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Sunitinib reverses type-1 immu ...... renal cell carcinoma patients.

@en

Sunitinib reverses type-1 immu ...... renal cell carcinoma patients.

@nl

type

label

Sunitinib reverses type-1 immu ...... renal cell carcinoma patients.

@en

Sunitinib reverses type-1 immu ...... renal cell carcinoma patients.

@nl

prefLabel

Sunitinib reverses type-1 immu ...... renal cell carcinoma patients.

@en

Sunitinib reverses type-1 immu ...... renal cell carcinoma patients.

@nl

P1433

Q46312545-29E1C8F2-0A29-43AF-B6EF-AD39EE97E66B

P1476

Q46312545-BF151739-35D2-4AE3-9332-D0B01B638C19

P2093

Q46312545-03030CCA-E8E3-4E56-B844-429A985EB692

Q46312545-22387B21-DDBB-4884-9732-9F69078DC3B4

Q46312545-2FD239EC-CD76-4C56-B07F-4A7EFBBCAB5E

Q46312545-38F7AF2E-C5D0-457F-BEFC-87A15D7AF9D7

Q46312545-746FE41C-3730-4409-BF17-6502B672BD06

Q46312545-91262743-101C-4255-BC2A-A8BEA750FAF8

Q46312545-939A1CCA-1C40-49B5-844A-04DDE34C7B45

Q46312545-AEEBCB43-6200-43BF-B523-8EDD3AE70532

Q46312545-B2A99EC3-6A8D-47EB-B09C-2F2D949AE8B7

Q46312545-B64A8847-2343-4EC9-A503-E42B9BE80F0D

P304

Q46312545-AA4E3AEE-7A81-4237-A79C-F9C64D8762FA

P31

Q46312545-1E743600-502A-4EFC-9732-D1F009A2259D

P356

Q46312545-5A929435-1257-4D6F-8EDD-5070DC3B9B35

P407

Q46312545-82A1B5D0-955A-4D73-98A1-425AC97BDA5B

P433

Q46312545-FE06CF90-ED96-4079-97F4-86F0986E9475

P478

Q46312545-1D20859F-73E2-4F3E-B8B1-5C32359A7846

P577

Q46312545-42BB12AC-820E-4E2E-A351-623BBED58372

P5875

Q46312545-85604C86-1C5E-4EF6-8CDE-AA2671479447

P698

Q46312545-08137154-462D-4E41-93A6-047BDF2DB8C8

P921

Q46312545-1BB19426-A5F4-4468-9B7E-7FD87D9658AA

P356

1078-0432.CCR-07-5212

P1433

Clinical Cancer Research

P1476

Sunitinib reverses type-1 immu ...... renal cell carcinoma patients.

@en

P2093

Ali Golshayan

http://www.w3.org/2001/XMLSchema#string

Amy Richmond

http://www.w3.org/2001/XMLSchema#string

Brian Rini

http://www.w3.org/2001/XMLSchema#string

James H Finke

http://www.w3.org/2001/XMLSchema#string

Joanna Ireland

http://www.w3.org/2001/XMLSchema#string

Jorge Garcia

http://www.w3.org/2001/XMLSchema#string

Laura Wood

http://www.w3.org/2001/XMLSchema#string

Patricia Rayman

http://www.w3.org/2001/XMLSchema#string

Paul Elson

http://www.w3.org/2001/XMLSchema#string

Robert Dreicer

http://www.w3.org/2001/XMLSchema#string

P304

6674-6682

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-07-5212

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23389440

http://www.w3.org/2001/XMLSchema#string

P698

18927310

http://www.w3.org/2001/XMLSchema#string

P921